She thanked the investigators for providing evidence to support the use of newer medications in children with refractory rheumatic diseases and expressed her hope for continued innovative therapies and future studies.
Elizabeth Sloan, MD, is an instructor in the Division of Pediatric Rheumatology, UT Southwestern Medical Center, Dallas, where she also completed her rheumatology fellowship. Dr. Sloan has served on the ACR’s Special Committee on Pediatric Rheumatology, as well as the Fellows-in-Training Subcommittee of the Committee on Rheumatology Training and Workforce Issues.
References
- Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: Version 2. Arthritis Rheumatol. 2021 Apr;73(4):e13–e29.
- Wahezi DM, Lo MS, Rubinstein TB, et al. American College of Rheumatology guidance for the management of pediatric rheumatic disease during the COVID-19 pandemic: Version 2. Arthritis Rheumatol. 2021 Aug;73(8):e46–e59.
- Son MBF, Murray N, Friedman K, et al. Multisystem inflammatory syndrome in children—initial therapy and outcomes. N Engl J Med. 2021 Jul 1;385(1):23–34.
- Wahezi DM, Peskin M, Tanner T. The impact of the COVID-19 pandemic on the field of pediatric rheumatology. Curr Opin Rheumatol. 2021 Sep 1;33(5):446–452.
- Banerjee D, Sasidharan A, Abdulhamid A, et al. Diagnostic yield of saliva for SARS-CoV-2 molecular testing in children. J Pediatric Infect Dis Soc. 2021 Nov 11; 10(10):967–969.
- Rubinstein TB, Bullock DR, Ardalan K, et al. Adverse childhood experiences are associated with childhood-onset arthritis in a national sample of US youth: An analysis of the 2016 National Survey of Children’s Health. J Pediatr. 2020 2020 Nov;226:243–250.e2.
- Chang JC, Xiao R, Burnham JM, Weiss PF. Longitudinal assessment of racial disparities in juvenile idiopathic arthritis disease activity in a treat-to-target intervention. Pediatr Rheumatol Online J. 2020 Nov 13;18(1):88.
- Padilla LA, Collins JL, Idigo AJ, et al. Kawasaki disease and clinical outcome disparities among Black children. J Pediatr. 2021 Feb;229:54–60.e2.
- Kimura Y, Schanberg LE, Tomlinson GA, et al. Optimizing the start time of biologics in polyarticular juvenile idiopathic arthritis: A comparative effectiveness study of Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans. Arthritis Rheumatol. 2021 Oct;73(10):1898–1909.
- Ong MS, Ringold S, Kimura Y, et al. Improved disease course associated with early initiation of biologics in polyarticular juvenile idiopathic arthritis: Trajectory analysis of a Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans study. Arthritis Rheumatol. 2021 Oct;73(10):1910–1920.
- Quartier P, Alexeeva E, Constantin T, et al. Tapering canakinumab monotherapy in patients with systemic juvenile idiopathic arthritis in clinical remission: Results from a phase IIIb/IV open-label, randomized study. Arthritis Rheumatol. 2021 Feb;73(2):336–346.
- Singh R, Ivaturi VD, Penzenstadler J, et al. Response similarity assessment between polyarticular juvenile idiopathic arthritis and adult rheumatoid arthritis for biologics. Clin Pharmacol Ther. 2021 Jul;110(1):98–107.
- Randell RL, Singler L, Cunningham A, et al. Delivering clinical trials at home: Protocol, design and implementation of a direct-to-family paediatric lupus trial. Lupus Sci Med. 2021 May;8(1):e000494.
- Li SC, Torok KS, Ishaq SS, et al. Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma. Rheumatology (Oxford). 2021 Aug;60(8):3817–3825.
- Zulian F, Dal Pozzolo R, Meneghel A, et al. Rituximab for rapidly progressive juvenile systemic sclerosis. Rheumatology (Oxford). 2020 Dec 1;59(12):3793–3797.
- Kim H, Dill S, O’Brien M, et al. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Ann Rheum Dis. 2021;80(3):406–408.
